Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659750 · ClinicalTrials.gov registry record · Phase 3
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 418
- Enrollment target
NCT00659750 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 418 participants.
The verdict
NCT00659750, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 418 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with PAR. The secondary objectives are to evaluate Quality-of-Life and safety.
Interventions
- DRUG Placebo
- DRUG Ciclesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659750
The ClinicalTrials.gov registry entry for NCT00659750 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00659750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659750 about?
NCT00659750 is a clinical study titled "To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)". The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with PAR. The secondary objectives are to evaluate Quality-of-Life and safety.
What is the current status of trial NCT00659750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 418 participants. The study started on 2003-12. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00659750?
The interventions under investigation include: Placebo (DRUG), Ciclesonide (DRUG).
Who is sponsoring clinical trial NCT00659750?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.